←
Timothy Lu338 posts
Timothy Lu avatar

Timothy Lu

@timlu

Synthetic Biologist | Biotech Entrepreneur | MIT Professor

◷ Joined April 2007▧ 9 Photos and videos
Senti Biosciences avatar
⟳ Timothy Lu retweeted
Senti Biosciences@SentiBio·11 Dec 2025

Dr. Kanya Rajangam, Chief Medical Officer, emphasized that the encouraging SENTI-202 data support advancement into pivotal studies and exploration across additional patient populations, enabled by recent RMAT and Orphan Drug Designations. bit.ly/3XFf7ST $SNTI #ASH2025

Post attachment
Timothy Lu avatar
Timothy Lu@timlu·11 Dec 2025

Thanks to Dr. Farhad Ravandi from @MDAndersonNews for sharing thoughts on the potential for $SNTI's SENTI-202 product to transform the treatment of AML and other cancers. Published by @VJHemOnc vjhemonc.com/video/nvzwt-dus…

Timothy Lu avatar
Timothy Lu@timlu·11 Dec 2025

Thanks to @GeneOnlineNews for highlighting @SentiBio 's recent SENTI-202 data for R/R AML @ ASH. With 50% ORR, RMAT designation, favorable safety, off-the-shelf delivery, we hope to advance this program quickly into pivotal studies for patients in need geneonline.com/senti-bio-win…

Timothy Lu avatar
Timothy Lu@timlu·10 Dec 2025

$SNTI recently reported our Logic Gated SENTI-202 cell therapy achieved 50% ORR, 42% CR/CRh, 7.6 month cCR durability in heavily pretreated refractory/refractory AML patients at #ASH25. This is an exciting new treatment modality for R/R AML, a disease with a median OS ~5 months

Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep, durable responses and a favorable safety profile in R/R AML, underscoring its potential to selectively target AML cells while preserving healthy ones. bit.ly/3XFf7ST $SNTI #AML #ASH2025

Post attachment
Timothy Lu avatar
Timothy Lu@timlu·28 Apr 2025

Excited to share updates on Senti Bio’s SENTI-202 program with Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML. Come join us at 830 AM ET webinar! $SNTI investors.sentibio.com/news-…

Senti Biosciences avatar
⟳ Timothy Lu retweeted
Senti Biosciences@SentiBio·3 Apr 2025

Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025 bit.ly/3QYtOx5 @AACR

Post attachment
Timothy Lu avatar
Timothy Lu@timlu·3 Apr 2025

Excited to share the latest clinical and preclinical data on our Logic Gated SENTI-202 product at the upcoming AACR meeting!

Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025 bit.ly/3QYtOx5 @AACR

Post attachment
Timothy Lu avatar
Timothy Lu@timlu·3 Dec 2024

Very excited to share details on SENTI-202 clinical trial - 2 of 3 pts achieved MRD negative CR in 1st dose level evaluated with a generally well-tolerated preliminary safety profile. Both patients continue to maintain remission (4+ and 3+ months, respectively). $SNTI

Today, we announced positive initial clinical data from the Phase 1 trial of SENTI-202, a potential first-in-class, off-the-shelf #CARNK #celltherapy for R/R hematologic malignancies, including #AML. Learn more on our webcast on Dec. 3 at 7:30am ET: bit.ly/4eUaKtb $SNTI

Post attachment
Timothy Lu avatar
Timothy Lu@timlu·3 Dec 2024

Excited to share the detailed data on SENTI-202 with Dr. Stephen Strickland and Dr. Kanya Rajangam. Join us to learn about how our #genecircuits enhanced CAR-NK therapies have the potential to transform the treatment of cancer through Logic Gating. $SNTI

Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: bit.ly/4eUaKtb $SNTI

Post attachment
Senti Biosciences avatar
⟳ Timothy Lu retweeted
Senti Biosciences@SentiBio·3 Dec 2024

Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: bit.ly/4eUaKtb $SNTI

Post attachment
Timothy Lu avatar
Timothy Lu@timlu·28 Aug 2023

Check out how $SNTI's Logic Gates precisely discriminate between cancer cells and healthy cells, allowing us to achieve highly precise cancer therapeutics! #synbio

At Senti, we envision a world where #cancer patients can access smarter therapies that precisely kill their cancer cells and spare their healthy cells. Watch to learn how we're utilizing our proprietary Logic Gating technology to design #CARNK cell therapies to achieve this goal.

1:07